Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDO-67 tamoxifen window-of-opportunity study in ER-positive breast cancer
NL-OMON60172Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Erasmus MC. Primary endpoints: Endoxifen levels after standard tamoxifen exposure, Tamoxifen resistance by Ki67 after 3 weeks and 1 more. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60172.